Genentech to Invest US$2 Billion in North Carolina, USA
Introduction:
Genentech has announced plans to invest approximately US$2 billion to expand its manufacturing facility in Holly Springs, North Carolina, USA.
Features:
The project involves the expansion of a manufacturing facility to increase production capacity for next-generation biopharmaceutical treatments.
The facility will focus on the production of therapies for metabolic conditions, including obesity, using advanced biomanufacturing processes.
Advanced digital manufacturing tools will support improved operational monitoring and process optimisation.
The expanded site will support domestic biopharmaceutical manufacturing and the supply of innovative medicines.
Additional upstream and downstream bioprocessing systems will be installed to support large-scale biologics production.
Production systems will support the manufacture of biologic medicines using advanced processing technologies.
Digital manufacturing platforms will assist in process control and production management.
The site is scheduled to become operational by 2029.
Specifications:
| Name | Genentech |
| Type | New Construction |
| Budget | US$2 billion |
| Year | 2029 |
